Arrowhead Receives Regulatory Approval to Begin Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520

[at noodls] – About ARC-520 Arrowhead’s RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins. The goal is to achieve … more

View todays social media effects on ARWR

View the latest stocks trending across Twitter. Click to view dashboard

See who Arrowhead is hiring next, click here to view